Trials / Active Not Recruiting
Active Not RecruitingNCT04639180
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 687 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab | Subjects receive Camrelizumab intravenously, Dosage form: lyophilized powder |
| DRUG | Rivoceranib (Apatinib) | Subjects receive Rivoceranib (Apatinib) orally, Dosage form: tablet |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2020-11-20
- Last updated
- 2025-12-30
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04639180. Inclusion in this directory is not an endorsement.